Psoriasis is a non-contagious inflammatory skin disease linked to a genetic predisposition and which develops under the influence of environmental parameters. While no treatment can completely cure this autoimmune disease, psoriasis is the subject of intensive research and especially so since the identification of subpopulations of Th17 and Th22 lymphocytes.
Psoriasis: in vitro models and assays
With the assistance of its academic partners (Laboratoire Inflammation, Tissus Epithéliaux et Cytokines, LITEC, EA 4331) and hospital partners (University Hospital Center of Poitiers), QIMA Life Sciences has carried out an extensive research program on psoriasis for more than a decade. Our work is particularly aimed at better characterizing the role as well as the individual or combined effects of Th1, Th17 and Th22 cytokines (e.g. IL-17A, IL-22, IL-1alpha, OSM and TNF-alpha) on the development of cutaneous inflammation and inhibition of skin differentiation. Today QIMA Life Sciences offers a full range of innovative models and in vitro pharmacology assays specifically dedicated to the evaluation of pharmacological efficacy (screening, profiling, proof-of-concept) of your products (APIs, biosimilars, formulations, medical devices):
- Immune response (Th17/Th22 cytokine release)
- Induction in keratinocytes (or reconstructed epidermis) of a psoriasis-like profile by cytokines
- Production of chemokines, antimicrobial peptides (AMPs) and expression of epidermal differentiation markers
- Specific marker analysis by immunoassays or RT-qPCR
Here are a few examples among all the standard assays proposed by QIMA Life Sciences in the field of psoriasis:
Psoriasis: clinical bioanalysis
Analysis of markers of inflammation
Our company has developed ready-to-use non-invasive collection kits to analyze the lipids and biomarkers of the skin surface from your samples or from those of your clinical center.
The markers of inflammation are also analyzed from samples using the SW Kit (cytokines, cascade of fatty acids, PGE2).
These evaluations help support your claims about the efficacy of soothing skincare products, protective products, anti-inflammatory products, etc.
Screening of inflammation markers
Interleukin-17A-induced production of acute serum amyloid A by keratinocytes contributes to psoriasis pathogenesisPsoriasis
Acute-serum Amyloid A (A-SAA), one of the major acute-phase proteins, is mainly produced in the liver but extra-hepatic synthesis involving the skin has been reported. Its expression is regulated by the transcription factors NF-κB, C/EBPβ, STAT3 activated by proinflammatory cytokines.
Imiquimod-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasomePsoriasis
The pathogenesis of inflammatory skin diseases such as psoriasis involves the release of numerous proinflammatory cytokines, including members of the IL-1 family. Here we report overexpression of IL-1α, IL-1β, and IL-1 receptor antagonist mRNA, associated to expression of IL-23p19, IL-17A, and IL-22 in skin cells
Inhibition of keratinocyte differentiation by the synergistic effect of IL-17A, IL-22, IL-1α, TNFα and oncostatin MInflammation, Psoriasis
This study highlights the precise role of cytokines in the skin inflammatory response (psoriasis). IL-22 and OSM more specifically drive epidermal hyperplasia and differentiation loss while IL-1α, IL-17A and TNFα were more involved in the activation of innate immunity.
Contribution of IL22 to experimental skin inflammationInflammation, Psoriasis
Focused on in vitro human models, we present the mechanisms of action of IL22 as well as its involvement in structure, metabolism, differentiation, chemotaxis, antibacterial activity, innate immunity, and tissue remodeling of epidermis.
Keratinocytes under fire of proinflammatory cytokines: Bonafide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasisAtopic dermatitis, Dermatite atopique, Psoriasis
Specific cytokine environment deregulation plays a central role on skin morphology and innate immunity, moving towards specific pathologies and opening the way to new therapeutic strategies.
Skin inflammation induced by the synergistic action of IL17A, IL22, OSM, IL1α and TNFα recapitulates some features of psoriasisPsoriasis
Our results demonstrate the important potentiating activities of IL17A, IL22, oncostatin M, TNF-alpha, and IL1alpha on keratinocytes. This is particularly interesting in the context of psoriasis where these cytokines are overexpressed and could synergize to play an important role in upregulation of chemokines and antimicrobial peptides production.
Keratinocytes as targets for cytokines in skin inflammationAcne, Atopic dermatitis, Dermatology, Psoriasis
Current knowledge about the effects of different cytokine families on keratinocytes, and more particularly theirinvolvement in skin inflammation and in the development of inflammatory skin diseases such as psoriasis
Cytokine-induced CEACAM1 expression on keratinocytes is characteristic for psoriatic skin and contributes to a prolonged lifespan of neutrophilsPsoriasis
These results show that cytokine-induced cell-surface expression of CEACAM1 by keratinocytes in the context of a psoriatic environment might contribute to the persistence of neutrophils and thus to ongoing inflammation and the decreased propensity for skin infection, typical for patients with psoriasis.
A role for T cell-derived interleukin 22 in psoriatic skin inflammationPsoriasis
This study indicate that interleukin 22 is a cytokine produced by skin-infiltrating lymphocytes that is potentially involved in initiation and/or maintenance of the pathogenesis of psoriasis.
OSM (Oncostatin M) secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammationPsoriasis
These results demonstrate that OSM and its receptor play an important role in cutaneous inflammatory responses in general and that the specific effects of OSM are associated with distinct inflammatory diseases depending on the cytokine environment.
Keratinocytes as targets for IL10-related cytokines : a putative role in psoriasis pathogenesisPsoriasis
In this review, we discuss recent knowledge about the effects of cytokines of the IL-10 family on keratinocytes and their potential role in psoriasis, a cutaneous inflammatory disease.
IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytesInflammation, Psoriasis
IL-22 belongs to a family of cytokines structurally related to IL-10, including IL-19, IL-20, IL-24, and IL-26. In contrast to IL-10, IL-22 has proinflammatory activities. IL-22 signals through a class II cytokine receptor composed of an IL-22-binding chain, IL-22RA1, and the IL-10RB subunit, which is shared with the IL-10R.